CLINTON BYBEE
CIK 1219043 · last filed 2022-08-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$445.58M
Companies
16
Total Filings
39
Lifetime Open-Market Net
$60.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | 10%+ Owner | 208,852 | $8.65 | $1.81M | $0 | 2 | 2022-08-16 |
| BEAM | 10%+ Owner | 2,949,630 | $26.46 | $78.06M | $0 | 1 | 2021-07-02 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 1,532,049 | $329.83 | $505.32M | $22.40M | 3 | 2021-01-12 |
| PI | Director | 17,125 | $136.07 | $2.33M | $97.7K | 14 | 2020-10-23 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 158,734 | $0.49 | $78.6K | $20.93M | 1 | 2020-09-22 |
| DNLI | 10%+ Owner | 10,668,749 | $23.85 | $254.45M | $0 | 1 | 2019-08-12 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 430,205 | $0.00 | $172 | -$2.94M | 1 | 2019-07-17 |
| Unity Biotechnology, Inc. (UBX) Delisted | 10%+ Owner | 629,860 | $0.20 | $126.0K | $0 | 1 | 2018-05-07 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | 10%+ Owner | 2,750,575 | — | — | $0 | 1 | 2017-08-01 |
| XTERA COMMUNICATIONS, INC. (XCOM) Delisted | Director | 1,885,090 | — | — | $7.50M | 5 | 2016-10-13 |
| VBI VACCINES INC. (VBIV) Delisted | 10%+ Owner | 134,928 | $0.07 | $8.8K | $0 | 1 | 2015-08-17 |
| PULM | 10%+ Owner | — | $1.70 | — | $0 | 1 | 2015-06-25 |
| Sage Therapeutics, Inc. (SAGE) Delisted | 10%+ Owner | 2,124,699 | $8.68 | $18.44M | $0 | 2 | 2015-06-22 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | 10%+ Owner | 64,377 | $0.01 | $773 | $12.76M | 1 | 2015-02-23 |
| AGIO | 10%+ Owner | 3,088,590 | $35.27 | $108.93M | $0 | 2 | 2015-02-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | 10%+ Owner | 7,347,015 | — | — | $0 | 1 | 2014-12-23 |
Recent Filings · Page 4 of 4
39 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-11-18 | XTERA COMMUNICATIONS, INC. (XCOM) Delisted | Mixed | +7,458,980 | $6.00M | EDGAR |
| 2015-08-17 | VBI VACCINES INC. (VBIV) Delisted | Grant (A) | +3,900,000 | $8.19M | EDGAR |
| 2015-06-25 | PULM | Grant (A) | — | $0 | EDGAR |
| 2015-06-22 | Sage Therapeutics, Inc. (SAGE) Delisted | Other (J) | −5,311,725 | $0 | EDGAR |
| 2015-02-23 | Bellerophon Therapeutics, Inc. (BLPH) Delisted | Buy (P) | +1,063,330 | $12.76M | EDGAR |
| 2015-02-23 | AGIO | Other (J) | −1,930,370 | $0 | EDGAR |
| 2014-12-23 | Juno Therapeutics, Inc. (JUNO) Delisted | Conv (C) | +52,276,875 | $0 | EDGAR |
| 2014-07-23 | Sage Therapeutics, Inc. (SAGE) Delisted | Conv (C) | +21,246,945 | $0 | EDGAR |
| 2013-07-31 | AGIO | Conv (C) | +19,303,690 | $0 | EDGAR |
Showing 31–39 of 39
Prev
Page 4 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.